BMY vs PTHS · P/E 17, rev $24.46B vs rev $16.8M
Bristol-Myers Squibb Company (BMY) versus Pelthos Therapeutics Inc. (PTHS) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Pelthos Therapeutics Inc. (PTHS) is a biotechnology company listed on AMEX.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported PTHS revenue for 2025-12-31 was $16.8M. Net income was -$43.3M. PTHS currently screens at market cap $94.7M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. PTHS currently screens at market cap $94.7M.
Not investment advice. Open the BMY and PTHS stock pages for the full models.
Not investment advice.